Recent news on Integrilin

Medicure Announces Appointment of Senior Advisor to Commercial ...  -  Apr 30, 2007
CCNMatthews (press release),Ms. Zell was instrumental in the launch of INTEGRILIN ® , a GP IIb/IIIa inhibitor. In 2006, INTEGRILIN ® sales exceeded US$300 million in the United States.

Premier Introduces New Tools for Managing Pharmacy Performance ...  -  Apr 30, 2007
dBusinessNews Charlotte (press release),...performance programs from seven more drug companies, including ReoPro ® from Eli Lilly and Company and Integrilin ® from Schering-Plough Corporation.

Aspirin Dose for the Prevention of Cardiovascular Disease  -  May 8, 2007
Journal of American Medical Association (subscription),...(GUSTO) IIb and the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Antagonism Using Integrilin Therapy (PURSUIT) trials (n = 20 521),

Millennium Reports Strong Financial and Operational Results for ...  -  26 Apr 2007
PharmaLive.com (press release),...the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement

Clopidogrel and Long-term Outcomes After Drug-Eluting Stent ...  -  Apr 24, 2007
Journal of American Medical Association (subscription),...data from the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial suggests that even modest

Millennium Discovers Biomarkers Potentially Predictive Of Response ...  -  Apr 18, 2007
Medical News Today (press release),...the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement

The Moose in the Room  -  Apr 16, 2007
Scientist,But a head to head clinical trial comparing ReoPro to a competing antithrombotic, Integrilin (eptifibatide), published in 1998, suggested that the two drugs

Harnessing the therapeutic power of venom  -  Apr 12, 2007
BiopharmaReporter.com,Other drugs tied to venoms include Schering-Ploughs Integrilin (eptifibatide), to treat acute coronary syndrome. That drug is a platelet glycoprotein

Schering-Plough Reports Financial Results for First Quarter of 2007  -  Apr 19, 2007
PR Newswire (press release),NASONEX 284 229 24% PEGINTRON 217 196 10% CLARINEX / AERIUS 204 160 28% TEMODAR 196 163 20% AVELOX 115 80 43% CLARITIN RX 112 101 11% INTEGRILIN 84 80

Millennium Exceeds Non-GAAP Profitability Goal and Narrows GAAP ...  -  Feb 8, 2007
Earthtimes.orgNote 4: Beginning September 1, 2005, in connection with the closing of the Company's transaction with Schering-Plough for INTEGRILIN, the Company no longer

Schering-Plough Reports Financial Results for 2006 Fourth Quarter ...  -  Jan 29, 2007
PR Newswire (press release),837 751 11% CLARINEX / AERIUS 164 139 18% 722 646 12% TEMODAR 189 160 18% 703 588 20% CLARITIN RX 78 85 (8%) 356 371 (4%) INTEGRILIN 85 71 20% 329 315

Millennium Looks Ahead  -  Jan 8, 2007
Motley Fool...in R&D and SG&A expenses, allowing more of its Velcade and Integrilin revenues to drop to the bottom line, when it made a bid for the company last year.

Millennium Achieves 2006 Non-GAAP Profitability, Reduces GAAP Net Loss  -  Jan 5, 2007
PharmaLive.com (press release),...the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement

SUNSET, SUNRISE  -  Dec 31, 2006
San Francisco Chronicle,During his 25-year career, he developed two drugs, Natrecor and Integrilin, used to prevent heart attacks and improve the lives of those facing heart

Millennium Initiates Phase II Trial to Evaluate MLN3897 in ...  -  26 Dec 2006
Yahoo! News (press release)...the commercial success of VELCADE and INTEGRILIN® (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement

Dr. Bob Tepper, President of R&D, to Leave Millennium  -  Dec 14, 2006
Drug Newswire (press release),...the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement

Dr. Bob Tepper, President of R&D, to Leave Millennium  -  Dec 14, 2006
Yahoo! News (press release)...government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN® (eptifibatide) Injection; achieving revenue consistent

Millennium Achieves Non-GAAP Profitability and Reduces GAAP Net ...  Oct 26, 2006
...in manufacturing the Company's products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide ... -MSN Money Millennium Pharmaceuticals Q3 2006 Earnings Call Transcript  Oct 26, 2006
This reduction was the result of our modified relationship with Schering-Plough around INTEGRILIN and the scale back of resources in G&A as a part of the ... -Seeking Alpha, Millennium and Ortho Biotech Enter into US Co-Promotion Agreement ...  Oct 26, 2006
...in manufacturing the products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN® (eptifibatide) Injection ... -Yahoo! News (press release) Millennium Issues Statement Regarding AnorMED Inc.  Oct 17, 2006
...government and third-party reimbursement rates; the commercial success of VELCADE® (bortezomib) for Injection and INTEGRILIN® (eptifibatide) Injection ... -Yahoo! News (press release) Schering-Plough Reports Financial Results for 2006 Third Quarter  Oct 20, 2006
NASONEX 221 170 30% 691 552 25% PEG-INTRON 206 185 11% 629 537 17% TEMODAR 179 152 18% 513 428 20% CLARINEX / AERIUS 171 157 9% 557 507 10% INTEGRILIN 82 86 (5 ... -PR Newswire (press release), Millennium Issues Statement Regarding AnorMed Inc.  Oct 17, 2006
...products; government and third-party reimbursement rates; the commercial success of VELCADE(R) (bortezomib) for Injection and INTEGRILIN(R) (eptifibatide ... -PharmaLive.com (press release), Journal of Clinical Oncology Publishes Final Study Results of ...  Oct 9, 2006
...in manufacturing the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide ... -Drug Newswire (press release), Heartscape Technologies Appoints Arthur Hiller, former Millennium ...  Sep 12, 2006
He successfully led the product re-branding and re-positioning of INTEGRILIN(R), a glycoprotein IIb-IIIa inhibitor agent for the treatment of patients with ... -Genetic Engineering News

Millennium Announces Phase I Trial Of MLN0415 For Inflammatory ...  Aug 31, 2006
...in manufacturing the Company's products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide ... -Medical News Today

Millennium Announces Phase I Trial of MLN0415 for Inflammatory ...  Aug 30, 2006
...the Company's products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN® (eptifibatide) Injection; achieving ... -Yahoo! News

VELCADE(R) (Bortezomib) for Injection Based Therapies Show ...  -  12 Dec 2006
Earthtimes.org...in manufacturing the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide ...

Millennium Initiates Phase II Trial To Evaluate MLN3897 In ...  -  Nov 29, 2006
Medical News Today (press release),...in manufacturing the Company's products; government and third- party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide ...

Blood thinner less risky for heart patients: study  -  Nov 24, 2006
Zee News,...include ReoPro, made by Johnson & Johnson and sold by Eli Lilly & Co., MGI Pharma Inc.'s Aggrastat and Millennium Pharmaceuticals Inc.'s Integrilin, which is ...

Blood thinner less risky for heart patients -study  -  Nov 22, 2006
ReutersMGI Pharma Inc.'s (MOGN.O: Quote, Profile, Research) Aggrastat and Millennium Pharmaceuticals Inc.'s (MLNM.O: Quote, Profile, Research) Integrilin, which is ...

Bayhill Therapeutics Names Robert S. King Vice President of ...  -  Nov 15, 2006
Genetic Engineering News (press release),...development at Millennium Pharmaceuticals in South San Francisco and COR Therapeutics, where he oversaw product development of INTEGRILIN(TM) injection from ...

Millennium Reports Strong Financial Results and Significant ...  Jul 27, 2006
Royalties associated with INTEGRILIN® (eptifibatide) Injection worldwide sales and VELCADE ex-US sales were $34.2 million for the second quarter 2006. ... -Yahoo! News

FDA Grants Priority Review To VELCADE(R) (Bortezomib) For ...  Aug 11, 2006
...in manufacturing the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide ... -Medical News Today

FDA Grants Priority Review to VELCADE(R) (Bortezomib) for ...  Aug 9, 2006
...the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN® (eptifibatide) Injection; achieving ... -Yahoo! News

Scientist who discovered nesiritide and eptifibatide dies  Jul 14, 2006
...the medicinal chemist who discovered two major cardiovascular drugs— nesiritide (Natrecor, Scios) and eptifibatide (Integrilin, Millennium Pharmaceuticals ... -TheHeart.Org

VELCADE(R) (Bortezomib) For Injection Showed Unprecedented Results ...  Jun 22, 2006
...in manufacturing the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide ... -Medical News Today

VELCADE(R) (Bortezomib) for Injection Showed Unprecedented Results ...  Jun 21, 2006
...the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN® (eptifibatide) Injection; achieving ... -Yahoo! News



Millennium's new focus on cancer drugs leads to Q1 revenue dip  Apr 27, 2006
Corp. on the two companies' jointly-developed drug Integrilin, which is designed to treat severe cardiovascular diseases. Millennium ... - Boston Business Journal

Millennium Achieves First Quarter 2006 Non-GAAP Profitability and ...  Apr 27, 2006
...of lower net reimbursement received from Schering-Plough Corporation for sales, marketing and development activities for INTEGRILIN® (eptifibatide) Injection. ... - Yahoo! News

Millennium Achieves First Quarter 2006 Non-GAAP Profitability and ...  Apr 27, 2006
...the result of lower net reimbursement received from Schering-Plough Corporation for sales, marketing and development activities for INTEGRILIN(R) (eptifibatide ... - PR Newswire

Aspirin dispute is fueled by funds of industry rivals  Apr 24, 2006
Patients classified as resistant will be placed into two groups -- one receiving Integrilin, an injectable anticlotting medication sold by Schering-Plough, and ... - Pittsburgh Post Gazette

Millennium and Johnson & Johnson Pharmaceutical Research and ...  Apr 18, 2006
...the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN® (eptifibatide) Injection; achieving ... - Yahoo! News

Schering-Plough Reports Financial Results for First Quarter of ...  Apr 20, 2006
278 220 26 NASONEX 229 183 25 PEG-INTRON 196 170 16 TEMODAR 163 131 25 CLARINEX / AERIUS 160 144 11 CLARITIN RX 101 111 (9) AVELOX 80 73 10 INTEGRILIN 80 75 6 ... - PR Newswire

Millennium and Johnson & Johnson Pharmaceutical Research and ...  Apr 18, 2006
...in manufacturing the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide ... - PR Newswire





Clopidogrel Treatment Prior to Percutaneous Coronary Intervention  Apr 4, 2006
Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) 4 and Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT ... - Journal of American Medical Association (subscription)

Angiomax better than other blood thinners: study  Mar 12, 2006
ReoPro, which is made by Johnson & Johnson and sold by Eli Lilly and Co., MGI Pharma Inc.'s Aggrastat and Millennium Pharmaceuticals Inc's Integrilin, which is ... - Reuters

Recommendations for Anticoagulated Patients Undergoing Image ...  Mar 21, 2006
...heparin. This class of antiplatelet drugs includes abciximab (ReoPro), eptifibatide (Integrilin), and tirofiban (Aggrastat). Normal ... - Am J Neuroradiology (subscription)

Doctors Test Sanofi, Bristol-Myers Drug to Save Heart Patients  Mar 8, 2006
...older blood-thinning medications whose revenues have stagnated, like ReoPro from New Brunswick, New Jersey-based Johnson & Johnson or Integrilin from Kenilworth ... - Bloomberg

The Medicines Company: hoping for a coronary coup  Mar 7, 2006
...the early addition of GPIIb/IIIa inhibitors such as Eli Lilly’s ReoPro (abciximab) and GlaxoSmithKline and Schering Plough’s Integrilin (eptifibatide) to ... - Pharmaceutical Business Review

Millennium Achieves $10 Million Milestone Payment  Mar 9, 2006
...in manufacturing the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide ... - PharmaLive.com

Millennium Achieves $10 Million Milestone Payment  Mar 9, 2006
...the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN® (eptifibatide) Injection; achieving ... - Yahoo! News



Eric Topol May Leave Cleveland Clinic  Feb 9, 2006
...people ), Plavix, from Sanofi-Aventis (nyse : SNY - news - people ), and both Eli Lilly's (nyse: LLY - news - people ) Reopro and Integrilin, from Millennium ... - Forbes

Schering Plough "peer perform," estimates reduced  Feb 1, 2006
...note published yesterday, the analyst mentions that the company's gross margins are expected to be adversely impacted in 2006 by the Integrilin royalty payments ... - New Ratings

Millennium Announces New Senior Vice President of Human Resources  09 Feb 2006
...in manufacturing the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide ... - PR Newswire

Eric Topol May Leave Cleveland Clinic  09 Feb 2006
...people ), Plavix, from Sanofi-Aventis (nyse : SNY - news - people ), and both Eli Lilly's (nyse: LLY - news - people ) Reopro and Integrilin, from Millennium ... - Forbes

Millennium Achieves 2005 Financial Guidance  Jan 26, 2006
...revenue of $123.5 million associated with the original collaboration agreement with Schering-Plough Corporation for INTEGRILIN® (eptifibatide) Injection. ... - Yahoo! News

Millennium Achieves 2005 Financial Guidance  Jan 26, 2006
...co-promotion revenue of $123.5 million associated with the original collaboration agreement with Schering-Plough Corporation for INTEGRILIN(R) (eptifibatide ... - PR Newswire

Schering-Plough posts profit, key drugs deliver  Jan 30, 2006
...the decline in the broader drug sector — due to lighter-than-expected revenue growth on lower sales for its anti-clotting treatment Integrilin and animal ... - ABC News

Schering-Plough Reports Financial Results for 2005 Fourth Quarter ...  Jan 30, 2006
...and commercialize golimumab with Centocor Inc., acquiring assets of NeoGenesis Pharmaceuticals and acquiring exclusive US rights to INTEGRILIN from Millennium ... - PR Newswire

Millennium Announces Appointments of Executive Vice President of ...  Jan 25, 2006
He joined Millennium in 2004 as the head of sales and marketing for INTEGRILIN® (eptifibatide) Injection, a product the Company sold the development and ... - Yahoo! News

Schering-Plough Swings to Profit  Jan 30, 2006
...primarily from product mix and supply chain process improvements, partly offset by the impact of the restructured agreement for Integrilin, which became ... - TheStreet.com

UPDATE 5-Schering-Plough posts profit, key drugs deliver  Jan 30, 2006
But the stock fell 2.5 percent due to lighter-than-expected revenue growth on lower sales for its anti-clotting treatment Integrilin and animal health business ... - Reuters

Schering-Plough Reports Financial Results For 2005  Jan 31, 2006
...primarily from product mix and supply chain process improvements, partly offset by the impact of the restructured agreement for INTEGRILIN, which became ... - CattleNetwork.com

Schering Plough "peer perform," estimates reduced  Feb 1, 2006
...note published yesterday, the analyst mentions that the company's gross margins are expected to be adversely impacted in 2006 by the Integrilin royalty payments ... - New Ratings

Arginox Appoints Robert Terifay as President and Chief Operating ...  Jan 6, 2006
...for establishment of the company's commercial presence in the acute care cardiovascular market, taking the company's first product, INTEGRILIN(R) (eptifibatide ... - PR Newswire

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional